MedTrace Logo

Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis

NCT06430671 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2025-07-03

No results posted yet for this study

Summary

RED4MS is a clinical trial to assess the safety and tolerability of autologous peptide coupled red blood cells (CLS12311) in patients with relapsing remitting multiple sclerosis (RRMS). CLS12311 consists of autologous red blood cells (RBCs) coupled with antigenic peptides and aims to treat RRMS by induction of antigen-specific immune tolerance.

Conditions

  • Relapsing-remitting Multiple Sclerosis (RRMS)

Interventions

DRUG

CLS12311 low

Peptide-coupled Red Blood Cells (RBCs)

DRUG

CLS12311 medium

Peptide-coupled Red Blood Cells (RBCs)

DRUG

CLS12311 high

Peptide-coupled Red Blood Cells (RBCs)

DRUG

uncoupled RBCs

autologous Red Blood Cells (RBCs)

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Scope International AG

    collaborator INDUSTRY

  • Tetec AG

    collaborator INDUSTRY

  • Jung Diagnostics GmbH

    collaborator INDUSTRY

  • Cellerys AG

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-18
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Czechia
  • Germany
  • Italy
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06430671 on ClinicalTrials.gov